Chirurgické přístupy k sarkomům hlavy a krku – současné koncepce a perspektivy

Stáhnout PDF English version

Autoři: J. Astl ^{1 3} ; J. Hložek ^1,2 ; L. Dzan ^1,2 ; D. Kovář ^1,2 ; J. Rotnágl ^1,2 ; L. Petruželka ⁴ ; R. Holý ^1,2
Působiště autorů: Department of Otorhinolaryngology and Maxilofacial Surgery, 3rd Faculty of Medicine, Charles University and Military University Hospital Prague, Prague ¹; Department of Ear, Nose and Throat, 3rd Faculty of Medicine, Charles University and Military University Hospital Prague, Prague ²; Department of Otolaryngology, Institute of Postgraduate Medical Education, University Motol Hospital, Prague ³; Department of Oncology, 1st Faculty of Medicine, Charles University and Military University Hospital Prague, Prague ⁴
Vyšlo v časopise: Otorinolaryngol Foniatr, 73, 2024, No. 3, pp. 167-175.
Kategorie: Přehledová práce
doi: https://doi.org/10.48095/ccorl2024167

Souhrn

Úvod a cíl: Sarkomy měkkých tkání představují neobvyklý typ malignity v oblasti hlavy a krku. Počet případů je popisován jako nízký. Mnoho autorů popisuje toto maligní onemocnění jako vzácný nádor hlavy a krku u dospělých. Na druhou stranu je sarkom součástí maligních onemocnění se špatnou prognózou v dětském, adolescentním a dospělém věku. Z literárních údajů vyplývá, že počty pacientů se sarkomy nelze přehlížet (27 908 případů za 7 let v Evropě na 500 mil. obyvatel). Sarkomy jsou sice málo častým zhoubným onemocněním, ale nejedná se o vzácné nádory. Proto potřebujeme aktuální poznatky a doporučení pro klinickou praxi v léčbě těchto heterogenních typů zhoubných mezenchymálních nádorů. Metoda: Analyzovali jsme literaturu o sarkomech hlavy a krku s využitím databáze Web of Science. Vyhledali jsme všechny práce popisující všechny typy léčby sarkomů v této oblasti. Tato studie analyzovala diagnostická kritéria sarkomů a léčebné plány sarkomů v oblasti hlavy a krku. Diskuze: Doporučení na základě mnoha faktorů. Sarkomy měkkých tkání v oblasti hlavy a krku jsou vzácné nebo málo časté. Incidence sarkomu měkkých tkání se pohybuje kolem 5 případů na 100 tis. obyvatel ročně. Musíme se zaměřit na nové znaky pro identifikaci rizikových faktorů sarkomu. Zásadní význam má proto patologické vyšetření a rozvoj molekulárních technik. Diagnostika na základě biopsie a histologie, včetně imunohistochemie a detekce specifických nádorových markerů. Doporučené zobrazovací metody: ultrazvuk, CT, HRCT, MR, PET CT. Přesná klasifikace a stratifikace musí být provedena v onkologickém týmu zahrnujícím patologa, onkologa, chirurga, radiologa. V literatuře byla uvedena obecná doporučení pro léčebný protokol a plánování léčby sarkomu hlavy a krku v závislosti na jeho velikosti, lokalizaci a biologickém chování. V literatuře byla popsána analýza údajů o základních léčebných modalitách v onkologické chirurgii, radioterapii a chemoterapii. V současné době nemáme k dispozici údaje o imunoterapii.

Klíčová slova:

terapie – léčba – diagnóza – doporučení – pokyny – sarkom hlavy a krku

Zdroje

1. Giannini L, Bresciani L, Paderno A et al. Head and neck adult-type soft tissues sarcomas: survival analysis and comparison between the last two editions of the TNM staging system. Eur Arch Otorhinolaryngol 2021; 278 (8): 3003–3010. Doi: 10.1007/s00405-020-06452-3.

2. Stiller CA, Trama A, Serraino D et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2013; 49 (3): 684–695. Doi: 10.1016/j.ejca.2012.09.011.

3. Galy-Bernadoy C, Garrel R. Head and neck soft-tissue sarcoma in adults. Eur Ann Otorhinolaryngol Head Neck Dis 2016; 133 (1): 37–42. Doi: 10.1016/j.anorl.2015.09.003.

4. Rapidis AD. Sarcomas of the head and neck in adult patients: current concepts and future perspectives. Expert Rev Anticancer Ther 2008; 8 (8): 1271–1297. Doi: 10.1586/14737140.8.8.1271.

5. Peng KA, Grogan T, Wang MB. Head and neck sarcomas: analysis of the SEER database. Otolaryngol Head Neck Surg 2014; 151 (4): 627–633. Doi: 10.1177/0194599814545747.

6. Coca-Pelaz A, Makitie AA, Strojan P et al. Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review. Adv Ther 2021; 38 (1): 90–108. Doi: 10.1007/s12325-020-01556-y.

7. Andersen S, Mann H, Krarup-Hansen A et al. Patient and Tumour Characteristics of Adult Head and Neck Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis. Sarcoma 2019; 9725637. Doi: 10.1155/2019/9725637.

8. Farhood AI, Hajdu SI, Shiu MH et al. Soft tissue sarcomas of the head and neck in adults. Am J Surg 1990; 160 (4): 365–369. Doi: 10.1016/s0002-9610 (05) 80544-6.

9. Patel SG, Shaha AR, Shah JP. Soft tissue sarcomas of the head and neck: an update. Am J Otolaryngol 2001; 22 (1): 2–18. Doi: 10.1053/ajot. 2001.20699.

10. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17 (6): 1471–1474. Doi: 10.1245/s10434-010-0985-4.

11. Ryan JR. Staging of soft tissue sarcomas. New York: Springer 1983: 49–52.

12. Baker LH. Soft tissue sarcomas. New York: Springer 1983: 147. Doi: 10.1007/978-1-46 13-3882-6.

13. Brierley JD, Gospodarowicz MK, Wittekind Ch. TNM Classification of Malignant Tumours. 8th ed. New Jersey: Willey Blackwell 2016: 272.

14. Cates JMM. Staging soft tissue sarcoma of the head and neck: Evaluation of the AJCC. 8th edition revised T classifications. Head Neck 2019; 41 (7): 2359–2366. Doi: 10.1002/hed.25701.

15. Shuman AG, Brennan MF, Palmer FL et al. Soft tissue sarcoma of the head & neck: nomogram validation and analysis of staging systems. J Surg Oncol 2015; 111 (6): 690–695. Doi: 10.1002/jso.23868.

16. Scelsi CL, Wang A, Garvin CM et al. Head and Neck Sarcomas: A Review of Clinical and Imaging Findings Based on the 2013 World Health Organization Classification. AJR Am J Roentgenol 2019; 212 (3): 644–654. Doi: 10.2214/AJR.18.19894.

17. Vibhakar AM, Cassels JA, Botchu R et al. Imaging update on soft tissue sarcoma. J Clin Orthop Trauma 2021; 22: 101568. Doi: 10.1016/j.jcot.2021.101568.

18. Casali PG, Bielack S, Abecassis N et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl 4): iv79–iv95. Doi: 10.1093/annonc/mdy310.

19. Gazda P, Baujat B, Sarini J et al. Functional or radical surgical treatment of laryngeal chondrosarcoma, analysis of survival and prognostic factors: A REFCOR and NetSarc-ResOs multicenter study of 74 cases. Eur J Surg Oncol 2024; 50 (2): 107315. Doi: 10.1016/j.ejso.2023.107 315.

20. Giraldo-Roldan D, Louredo BVR, Penafort PVM et al. Low-Grade Myofibroblastic Sarcoma of the Oral and Maxillofacial Region: An International Clinicopathologic Study of 13 Cases and Literature Review. Head Neck Pathol 2023; 17 (3): 832–850. Doi: 10.1007/s12105-023-01 577-3.

21. Mamikunian G, Ziegler A, Block A et al. Risk Factors for Recurrence and the Role of Radiotherapy in Low-grade Myofibroblastic Sarcoma: A Systematic Review. Am J Clin Oncol 2023; 46 (9): 420–425. Doi: 10.1097/COC.0000000000001025.

22. Xu B, Pan Q, Pan H et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine 2023; 64: 102240. Doi: 10.1016/j.eclinm.2023.102 240.

23. Muller JA, Delank KS, Laudner K et al. Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry. J Cancer Res Clin Oncol 2023; 149 (19): 17051–17069. Doi: 10.1007/s00432-023-05 350-5.

24. Liu QK, Yu XJ, Wang YG et al. Risk factors for lymph node metastasis of soft tissue sarcomas of the head, neck, and extremities, and the clinical significance of negative lymph node dissection. J Orthop Surg Res 2022; 17 (1): 167. Doi: 10.1186/s13018-022-03050-3.

25. Evans LK, Sutton S, Echanique K et al. Cutaneous head and neck angiosarcoma: The 30-year UCLA experience. Laryngoscope Investig Otolaryngol 2023; 8 (6): 1557–1563. Doi: 10.1002/lio2.1173.

26. Houpe JE, Seger EW, Neill BC et al. Treatment of Angiosarcoma of the Head and Neck: A Systematic Review. Cutis 2023; 111 (5): 247–251. Doi: 10.12788/cutis.0767.

27. Barron K, Omiunu A, Celidonio J et al. Kaposi Sarcoma of the Larynx: A Systematic Review. Otolaryngol Head Neck Surg 2023; 168 (3): 269–281. Doi: 10.1177/01945998221105059.

28. Marcoval J, Moreno-Vilchez C, Torrecilla-Vall--Llosera C et al. Dermatofibrosarcoma Protuberans: A Study of 148 Patients. Dermatology 2024; 240 (3): 487–493. Doi: 10.1159/000536172.

29. Suzuki T, Noguchi N, Shirane S et al. Cervical Liposarcoma Revisited: A Case Report and Scoping Literature Review. Case Rep Oncol 2022; 15 (3): 881–886. Doi: 10.1159/000526862.

30. Gjorgova Gjeorgjievski S, Thway K, Dermawan JK et al. Pleomorphic Liposarcoma: A Series of 120 Cases with Emphasis on Morphologic Variants.. Am J Surg Pathol 2022; 46 (12): 1700–1705. Doi: 10.1097/PAS.0000000000 01962.

31. Radak M, Ghamari N, Fallahi H. Identification of common factors among fibrosarcoma, rhabdomyosarcoma, and osteosarcoma by network analysis. Biosystems 2024; 235: 105093. Doi: 10.1016/j.biosystems.2023.105093.

32. Hsu YC, Lu HF, Huang CC et al. Malignant lymphoepithelial lesions of the salivary gland. Otolaryngol Head Neck Surg 2006; 134 (4): 661–666. Doi: 10.1016/j.otohns.2005.10.034.

33. Arispe Angulo KR, Logan S, Bahrami A et al. Myxofibrosarcoma in adolescents and young adults: a clinicopathologic study of 17 cases. Hum Pathol 2023; 142: 90–95. Doi: 10.1016/ j.humpath.2023.09.005.

34. Battisti A, Della Monaca M, Di Giorgio D et al. Extranodal follicular dendritic cell sarcoma of the tonsil: An extremely rare clinical entity. Oral Oncol 2024; 149: 106690. Doi: 10.1016/j.oraloncology.2024.106690.

35. Sharma A, Vyas P, Agarwal D. Undifferentiated pleomorphic sarcoma of the floor of mouth: A rare case. J Oral Maxillofac Pathol 2023; 27 (Suppl 1): S33–S37. Doi: 10.4103/jomfp.jomfp_107_21.

36. Novillo M, Albergo JI, Huespe I. Resultados oncológicos y factores pronósticos en pacientes con sarcoma sinovial tratados quirúrgicamente. Medicina (B. Aires) 2023; 83 (5): 737–743.

37. Fujiwara T, Kunisada T, Nakata E et al. Advances in treatment of alveolar soft part sarcoma: an updated review. Jpn J Clin Oncol 2023; 53 (11): 1009–1018. Doi: 10.1093/jjco/hyad 102.

38. Koshyk O, Dehner CA, van den Hout M et al. EWSR1:: POU2AF3 (COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection. Mod Pathol 2023; 36 (12): 100337. Doi: 10.1016/j.modpat.2023.100337.

39. Yanzon A, Gomez NL, Picco P et al. Head and neck sarcomas: treatment outcomes in a tertiary referral center in Argentina. Oral Maxillofac Surg 2021; 25 (4): 509–518. Doi: 10.1007/s10006-021-00944-0.

40. Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol 2003; 15 (3): 239–252. Doi: 10.1097/00001622-20030 5000-00011.

41. Orton A, Wright J, Buchmann L et al. A Case of Complete Abscopal Response in High-Grade Pleiomorphic Sarcoma Treated with Radiotherapy Alone. Cureus 2016; 8 (10): e821. Doi: 10.7759/cureus.821.

42. Vazquez M, Baust K, Ilundain A et al. Pencil Beam Scanning Proton Therapy for Adolescents and Young Adults with Head and Neck Sarcomas. Int J Part Ther 2023; 10 (2): 73–84. Doi: 10.14338/IJPT-23-00010.1.

43. Astl J, Belsan T, Michnova L et al. Highly Aggressive Osteosarcoma of the Ethmoids and Maxillary Sinus-A Case of Successful Surgery and Proton Beam Radiotherapy in a 65-Year-Old Man. Medicina (Kaunas) 2022; 58 (9). Doi: 10.3390/medicina58091141.

44. Becquart O, Girard C, Lesage C et al. Angiosarcoma of the head and neck treated with bevacizumab and paclitaxel. Ann Dermatol Venereol 2018; 145 (6–7): 451–453. Doi: 10.1016/j.annder.2018.02.008.

45. Dietz A, Frerich B. [Current opinion in treatment of soft tissue sarcoma]. Laryngorhinootologie 2009; 88 (5): 293-302. Doi: 10.1055/s-0029-1216350.

46. Dietz A, Lethaus B, Pirlich M et al. Current Therapy Standards for Soft Tissue Sarcomas in the Head and Neck Area – Part 2. Laryngorhinootologie 2022; 101 (10): 820–831. Doi: 10.1055/a-1810-3790.

47. von Mehren M, Kane JM, Agulnik M et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (7): 815–833. Doi: 10.6004/jnccn.2022.0035.

78. Evidence-based Guidelines: Soft Tissue Sarcoma Version 1.1 – May 2022 AWMF-Registernummer: 032/044O German guidelinie programm.

49. Park JT, Roh JL, Kim SO et al. Prognostic factors and oncological outcomes of 122 head and neck soft tissue sarcoma patients treated at a single institution. Ann Surg Oncol 2015; 22 (1): 248–255. Doi: 10.1245/s10434-014-3870-8.

50. Han S, Yin X, Xu W et al. The Management of Head and Neck Sarcoma. J Craniofac Surg 2020; 31 (2): e189–e192. Doi: 10.1097/SCS.000000 0000006162.

51. Cannon RB, Kull AJ, Carpenter PS et al. Adjuvant radiation for positive margins in adult head and neck sarcomas is associated with improved survival: Analysis of the National Cancer Database. Head Neck 2019; 41 (6): 1873–1879. Doi: 10.1002/hed.25619.

52. Breakey RW, Crowley TP, Anderson IB et al. The surgical management of head and neck sarcoma: The Newcastle experience. J Plast Reconstr Aesthet Surg 2017; 70 (1): 78–84. Doi: 10.1016/j.bjps.2016.09.026.

53. Mahmoud O, Beck R, Kalyoussef E et al. Adjuvant therapies utilization pattern and survival outcomes in high-grade head and neck soft tissue sarcoma; a population-based study. Oral Oncol 2017; 66: 28–37. Doi: 10.1016/j.oral oncology.2016.12.030.

54. Callegaro D, Miceli R, Mariani L et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer 2017; 123 (15): 2802–2820. Doi: 10.1002/cncr.30721.

55. Williams L, Tmanova L, Mydlarz WK et al. Radiation-Associated Sarcoma of the Neck: Case Series and Systematic Review. Ann Otol Rhinol Laryngol 2018; 127 (10): 735–740. Doi: 10.1177/0003489418789966.

56. de Bree R, van der Valk P, Kuik DJ et al. Prognostic factors in adult soft tissue sarcomas of the head and neck: a single-centre experience. Oral Oncol 2006; 42 (7): 703–709. Doi: 10.1016/j.oraloncology.2005.11.009.

57. Astl J, Holy R, Tuckova I et al. Sarcomas of the Larynx: One Institution‘s Experience and Treatment Protocol Analyses. Medicina (Kaunas) 2021; 57 (3). Doi: 10.3390/medicina57030192.

58. Astl J, Synková B, Kovář D et al. Leiomyosarcoma of the Larynx – Diagnosis and Treatment Protocol A Case Report and Review of the Literature. Otorinolaryngol Foniatr 2019; 68 (2): 109–113.

59. Astl J, Dušková J, Límanová Z et al. Hemangiosarcoma of the Thyroid Gland. A case report. Neuroendocrinology Letters 2000; 21: 213–216.

60. Kalitova P, Plzak J, Kodet R et al. Angiosarcoma of the thyroid. Eur Arch Otorhinolaryngol 2009; 266 (6): 903-905. Doi: 10.1007/ s00405-008-0820-8.

ORCID authors

J. Astl 0000-0002-8022-0200,

J. Hložek 0000-0002-3584-9747,

L. Dzan 0000-0003-3034-1845,

D. Kovář 0000-0002-7370-264X,

J. Rotnágl 0000-0003-2692-0342,

L. Petruželka 0000-0002-4397-0635,

R. Holý 0000-0001-8073-3658.

Accepted for review: 7. 4. 2024

Accepted for printing: 28. 6. 2024

Richard Holý, MD, PhD.

Department of Otorhinolaryngology and Maxillofacial Surgery